Mark Wildgust on Culture as the Engine of Oncology Innovation at Johnson & Johnson
Key Insights
Mark Wildgust, VP of Global Medical Affairs, Oncology at Janssen, reflects on 27 years in oncology and the accelerating convergence of science, technology, and patient-centered care.
He emphasizes that organizational culture—built on clarity, purpose, empathy, and connectedness—is the essential engine driving sustainable innovation in cancer drug development.
Wildgust argues that breakthroughs are not only scientific but human, requiring environments where teams feel empowered and patients remain the central focus.
Mark Wildgust, Vice President of Global Medical Affairs, Oncology at The Janssen Pharmaceutical Companies (search) of Johnson and Johnson, marked a personal and professional milestone this week—27 years since moving to the United States—by sharing reflections on how culture, rather than science alone, serves as the foundational engine of innovation in oncology drug development.
Wildgust described the current moment in oncology as "a new era of innovation," where the convergence of science, technology, and patient-centered care is accelerating progress toward possibilities once considered out of reach. "We are not only extending lives – we are moving closer to cures," he stated, underscoring the ambition driving Johnson & Johnson Innovative Medicine's mission to "deliver better today's and more tomorrows."
Culture as the Engine of Breakthroughs
Central to Wildgust's perspective is the conviction that organizational culture determines the trajectory and sustainability of scientific progress. "Breakthroughs change outcomes. Culture changes what's possible," he wrote, arguing that the most enduring advances are not born solely from scientific discovery but from the culture that sustains it.
He characterized culture as "the quiet force that shapes how we show up for one another," defined by listening with empathy, challenging with curiosity, and supporting with conviction. "As a leader, I believe culture is the engine of innovation," Wildgust said. "Supporting teams with clarity, purpose, and connectedness ensures that breakthroughs are not just scientific, but human."
The Human Dimension of Drug Development
Wildgust emphasized that true transformation in cancer care emerges from how teams collaborate, challenge boundaries, and remain anchored in patient needs. "It is in the way we collaborate, the way we challenge boundaries, and the way we stay anchored in patients' needs that true transformation happens," he noted.
He further stressed that the environment created within research organizations—"one where teams feel empowered, patients remain our north star, and balance is valued"—is what transforms discovery into tangible clinical impact. "When culture inspires, innovation compounds. When culture uplifts, hope expands."
Resilience Through Restoration
Beyond team dynamics, Wildgust highlighted the often-overlooked role of individual restoration in sustaining innovation. "Taking time to pause, reflect, and restore ourselves is not a luxury – it's a necessity," he wrote. "Renewal fuels resilience, and resilience fuels the kind of culture where innovation thrives."
Looking Forward
Reflecting on his nearly three-decade journey in oncology, Wildgust expressed optimism about the field's trajectory. "Looking forward, I am inspired by the bold leaps we are making together – leaps that will redefine cancer care and bring us closer to a world where prevention, interception, and cures are within reach." He concluded that innovation demands vision, courage, and culture, adding, "I am proud to play my part in shaping all three."